Zobrazeno 1 - 3
of 3
pro vyhledávání: '"ALK rearrangement-positive NSCLC"'
Autor:
Sachi Okawa, Takuo Shibayama, Atsushi Shimonishi, Jun Nishimura, Taichi Ozeki, Kenji Takada, Hiroe Kayatani, Daisuke Minami, Ken Sato, Keiichi Fujiwara, Toshiro Yonei, Toshio Sato, Manabu Suno
Publikováno v:
Case Reports in Oncology, Vol 11, Iss 3, Pp 777-783 (2018)
Although crizotinib shows marked antitumor activity in anaplastic lymphoma kinase (ALK) rearrangement-positive non-small-cell lung cancer (NSCLC) patients, all treated patients ultimately develop resistance to this drug. Isolated central nervous syst
Externí odkaz:
https://doaj.org/article/a2b942ddf8934043b55665371f598498
Autor:
Kenji Takada, Takuo Shibayama, Hiroe Kayatani, Sachi Okawa, Ken Sato, Toshiro Yonei, Daisuke Minami, Jun Nishimura, Toshio Sato, Manabu Suno, Atsushi Shimonishi, Keiichi Fujiwara, Taichi Ozeki
Publikováno v:
Case Reports in Oncology, Vol 11, Iss 3, Pp 777-783 (2018)
Case Reports in Oncology
Case Reports in Oncology
Although crizotinib shows marked antitumor activity in anaplastic lymphoma kinase (ALK) rearrangement-positive non-small-cell lung cancer (NSCLC) patients, all treated patients ultimately develop resistance to this drug. Isolated central nervous syst
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ace2cb45abab66b3bdb52a3d1e4ded2f
https://www.karger.com/Article/FullText/492150
https://www.karger.com/Article/FullText/492150
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.